Emerging drugs for idiopathic pulmonary fibrosis

Bibliography

• Raghu G, Weycker D, Edelsberg J, Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-16
   PubMed Web of Science ®Google Scholar
• Gribbin J, Hubbard RB, Le Jeune I, Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61:980-5
   PubMed Web of Science ®Google Scholar
• Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest 2007;132:637-50
   PubMed Web of Science ®Google Scholar
• Selman M, Rojas M, Mora AL, Pardo A. Aging and interstitial lung diseases: unraveling an old forgotten player in the pathogenesis of lung fibrosis. Semin Respir Crit Care Med 2010;31:607-17
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Lezotte DC, Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176:277-84
   PubMed Web of Science ®Google Scholar
• Selman M, Carrillo G, Estrada A, Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007;2:e482
   PubMed Web of Science ®Google Scholar
• Collard HR, Moore BB, Flaherty KR, Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43
   PubMed Web of Science ®Google Scholar
• Song JW, Hong SB, Lim CM, Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors, and outcome. Eur Respir J 2010; 37(2):356-63
   PubMed Web of Science ®Google Scholar
• Boon K, Bailey NW, Yang J, Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009;4:e5134
   PubMed Web of Science ®Google Scholar
• Cottin V, Nunes H, Brillet PY, Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-93
   PubMed Web of Science ®Google Scholar
• Mejia M, Carrillo G, Rojas-Serrano J, Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-15
   PubMed Web of Science ®Google Scholar
• Cottin V, Le Pavec J, Prevot G, Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010;35:105-11
   PubMed Web of Science ®Google Scholar
• Harris JM, Johnston ID, Rudd R, Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010;65:70-6
   PubMed Web of Science ®Google Scholar
• Gotway MB, Freemer MM, King TE Jr. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax 2007;62:546-53
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol 2008;39:1275-94
   PubMed Web of Science ®Google Scholar
• Lawson WE, Loyd JE. Will the genes responsible for familial pulmonary fibrosis provide clues to the pathogenesis of IPF? Am J Respir Crit Care Med 2010;182:1342-3
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, Idiopathic pulmonary fibrosis: evidence based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; In press
   Google Scholar
• Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006;3:293-8
   PubMedGoogle Scholar
• Steele MP, Speer MC, Loyd JE, Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146-52
   PubMed Web of Science ®Google Scholar
• Hubbard R, Lewis S, Richards K, Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996;347:284-9
   PubMed Web of Science ®Google Scholar
• Baumgartner KB, Samet JM, Coultas DB, Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000;152:307-15
   PubMed Web of Science ®Google Scholar
• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006;3:364-72
   PubMedGoogle Scholar
• Strieter RM. What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc 2008;5:305-10
   PubMedGoogle Scholar
• Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-70
   PubMed Web of Science ®Google Scholar
• Gilani SR, Vuga LJ, Lindell KO, CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010;5:e8959
   PubMed Web of Science ®Google Scholar
• Zuo F, Kaminski N, Eugui E, Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99:6292-7
   PubMed Web of Science ®Google Scholar
• Wilson MS, Madala SK, Ramalingam TR, Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010;207:535-52
   PubMed Web of Science ®Google Scholar
• Lo Re S, Dumoutier L, Couillin I, IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J Immunol 2010;184:6367-77
   PubMed Web of Science ®Google Scholar
• Myers JL, Katzenstein AL. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest 1988;94:1309-11
   PubMed Web of Science ®Google Scholar
• Uhal BD, Joshi I, Hughes WF, Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998;275:L1192-9
   PubMed Web of Science ®Google Scholar
• Barbas-Filho JV, Ferreira MA, Sesso A, Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol 2001;54:132-8
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:350-6
   PubMedGoogle Scholar
• Nogee LM, Dunbar AE III, Wert SE, A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001;344:573-9
   PubMed Web of Science ®Google Scholar
• van Moorsel CH, van Oosterhout MF, Barlo NP, Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med 2010;182:1419-25
   PubMed Web of Science ®Google Scholar
• Wang WJ, Mulugeta S, Russo SJ, Beers MF. Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. J Cell Sci 2003;116:683-92
   PubMed Web of Science ®Google Scholar
• Mulugeta S, Nguyen V, Russo SJ, A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 2005;32:521-30
   PubMed Web of Science ®Google Scholar
• Korfei M, Ruppert C, Mahavadi P, Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:838-46
   PubMed Web of Science ®Google Scholar
• Lawson WE, Crossno PF, Polosukhin VV, Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008;294:L1119-26
   PubMed Web of Science ®Google Scholar
• Vannella KM, Moore BB. Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 2008;1:2
   PubMedGoogle Scholar
• Armanios MY, Chen JJ, Cogan JD, Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356:1317-26
   PubMed Web of Science ®Google Scholar
• Tsakiri KD, Cronkhite JT, Kuan PJ, Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104:7552-7
   PubMed Web of Science ®Google Scholar
• Alder JK, Chen JJ, Lancaster L, Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008;105:13051-6
   PubMed Web of Science ®Google Scholar
• Waisberg DR, Barbas-Filho JV, Parra ER, Abnormal expression of telomerase/apoptosis limits type II alveolar epithelial cell replication in the early remodeling of usual interstitial pneumonia/idiopathic pulmonary fibrosis. Hum Pathol 2010;41:385-91
   PubMed Web of Science ®Google Scholar
• Andersson-Sjoland A, de Alba CG, Nihlberg K, Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008;40:2129-40
   PubMed Web of Science ®Google Scholar
• Herzog EL, Bucala R. Fibrocytes in health and disease. Exp Hematol 2010;38:548-56
   PubMed Web of Science ®Google Scholar
• Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol 2010;42:535-42
   PubMed Web of Science ®Google Scholar
• Garcia-de-Alba C, Becerril C, Ruiz V, Expression of matrix metalloproteases by fibrocytes: possible role in migration and homing. Am J Respir Crit Care Med 2010;182:1144-52
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, The myofibroblast: one function, multiple origins. Am J Pathol 2007;170:1807-16
   PubMed Web of Science ®Google Scholar
• Willis BC, Liebler JM, Luby-Phelps K, Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005;166:1321-32
   PubMed Web of Science ®Google Scholar
• Kim KK, Kugler MC, Wolters PJ, Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:13180-5
   PubMed Web of Science ®Google Scholar
• Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L525-34
   PubMed Web of Science ®Google Scholar
• Sides MD, Klingsberg RC, Shan B, The Epstein-Barr Virus LMP 1 and TGF-{beta}1 Synergistically Induce EMT in Lung Epithelial Cells. Am J Respir Cell Mol Biol 2010
   Google Scholar
• Humphreys BD, Lin SL, Kobayashi A, Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010;176:85-97
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 2006;3:383-8
   PubMedGoogle Scholar
• Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008;153 Suppl 1:S367-78
   PubMedGoogle Scholar
• Scotton CJ, Krupiczojc MA, Konigshoff M, Increased local expression of coagulation Factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009;119:2550-63
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008;5:e62
   PubMed Web of Science ®Google Scholar
• Konigshoff M, Balsara N, Pfaff EM, Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008;3:e2142
   PubMed Web of Science ®Google Scholar
• Konigshoff M, Kramer M, Balsara N, WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009;119:772-87
   PubMed Web of Science ®Google Scholar
• Koli K, Myllarniemi M, Vuorinen K, Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 2006;169:61-71
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64
   PubMed Web of Science ®Google Scholar
• Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003:CD002880. Edited; published in Issue 2, 2010
   Google Scholar
• Spagnolo P, Del Giovane C, Luppi F, Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010:CD003134
   Google Scholar
• Raghu G, Depaso WJ, Cain K, Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6
   PubMed Web of Science ®Google Scholar
• Tirouvanziam R, Conrad CK, Bottiglieri T, High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006;103:4628-33
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42
   PubMed Web of Science ®Google Scholar
• Behr J, Demedts M, Buhl R, Lung function in idiopathic pulmonary fibrosis-extended analyses of the IFIGENIA trial. Respir Res 2009;10:101
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291:367-73
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211-18
   PubMed Web of Science ®Google Scholar
• Nakazato H, Oku H, Yamane S, A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002;446:177-85
   PubMed Web of Science ®Google Scholar
• Oku H, Nakazato H, Horikawa T, Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002;446:167-76
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159:1061-9
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9
   PubMed Web of Science ®Google Scholar
• InterMune, Inc. Sponsor's Briefing Document for the FDA Pulmonary-Allergy Drugs Advisory Committee Meeting (NDA 22-535); 9 March 2010
   Google Scholar
• Clark JG, Dedon TF, Wayner EA, Carter WG. Effects of interferon-gamma on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J Clin Invest 1989;83:1505-11
   PubMed Web of Science ®Google Scholar
• Narayanan AS, Whithey J, Souza A, Raghu G. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest 1992;101:1326-31
   PubMed Web of Science ®Google Scholar
• Okada T, Sugie I, Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res 1993;12:87-91
   PubMedGoogle Scholar
• Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995;21:791-808
   PubMed Web of Science ®Google Scholar
• Ziesche R, Hofbauer E, Wittmann K, A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Bradford WZ, A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33
   PubMed Web of Science ®Google Scholar
• King TE Jr, Albera C, Bradford WZ, Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8
   PubMed Web of Science ®Google Scholar
• Day E, Waters B, Spiegel K, Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599:44-53
   PubMed Web of Science ®Google Scholar
• Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38:(Suppl 5):S28-36
   PubMed Web of Science ®Google Scholar
• Aono Y, Nishioka Y, Inayama M, Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171:1279-85
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-10
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Denton CP, Dashwood MR, Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-25
   PubMed Web of Science ®Google Scholar
• Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997;156:600-8
   PubMed Web of Science ®Google Scholar
• King TE Jr, Behr J, Brown KK, BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75-81
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-55
   PubMed Web of Science ®Google Scholar
• Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010;9:956-70
   PubMed Web of Science ®Google Scholar
• Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002;3:13
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Roth GJ, Hilberg F, Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007;29:976-85
   PubMed Web of Science ®Google Scholar
• Moeller A, Ask K, Warburton D, The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40:362-82
   PubMed Web of Science ®Google Scholar
• Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L152-60
   PubMed Web of Science ®Google Scholar
• Hecker L, Vittal R, Jones T, NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-81
   PubMed Web of Science ®Google Scholar
• Pache JC, Carnesecchi S, Deffert C, NOX-4 is expressed in thickened pulmonary arteries in idiopathic pulmonary fibrosis. Nat Med 2011;17:31-2; author reply 2-3
   PubMed Web of Science ®Google Scholar
• Amara N, Goven D, Prost F, NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65:733-8
   PubMed Web of Science ®Google Scholar
• Laleu B, Gaggini F, Orchard M, First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53:7715-30
   PubMed Web of Science ®Google Scholar
• Hinz B. Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep 2009;11:120-6
   PubMedGoogle Scholar
• Kagan HM, Li WD. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010;16:1009-17
   PubMed Web of Science ®Google Scholar
• Kubo H, Nakayama K, Yanai M, Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82
   PubMed Web of Science ®Google Scholar
• Imokawa S, Sato A, Hayakawa H, Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997;156:631-6
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez NA, Cambrey AD, Harrison NK, Role of thrombin in pulmonary fibrosis. Lancet 1995;346:1071-3
   PubMed Web of Science ®Google Scholar
• Howell DC, Goldsack NR, Marshall RP, Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001;159:1383-95
   PubMed Web of Science ®Google Scholar
• Gunther A, Lubke N, Ermert M, Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003;168:1358-65
   PubMed Web of Science ®Google Scholar
• Blanc-Brude OP, Chambers RC, Leoni P, Factor Xa is a fibroblast mitogen via binding to effector-cell protease receptor-1 and autocrine release of PDGF. Am J Physiol Cell Physiol 2001;281:C681-9
   PubMed Web of Science ®Google Scholar
• Chambers RC, Leoni P, Blanc-Brude OP, Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 2000;275:35584-91
   PubMed Web of Science ®Google Scholar
• Jenkins RG, Su X, Su G, Ligation of protease-activated receptor 1 enhances alpha(v)beta(6) integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006;116:1606-14
   PubMed Web of Science ®Google Scholar
• Howell DCJ, Johns RH, Lasky JA, Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005;166:1353-65
   PubMed Web of Science ®Google Scholar
• Becker RC, Moliterno DJ, Jennings LK, Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled Phase II study. Lancet 2009;373:919-28
   PubMed Web of Science ®Google Scholar
• Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003;171:5537-46
   PubMed Web of Science ®Google Scholar
• Pilling D, Roife D, Wang M, Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007;179:4035-44
   PubMed Web of Science ®Google Scholar
• Wang J, Jiao H, Stewart TL, Improvement in postburn hypertrophic scar after treatment with IFN-alpha2b is associated with decreased fibrocytes. J Interferon Cytokine Res 2007;27:921-30
   PubMed Web of Science ®Google Scholar
• Katebi M, Fernandez P, Chan ES, Cronstein BN. Adenosine A2A receptor blockade or deletion diminishes fibrocyte accumulation in the skin in a murine model of scleroderma, bleomycin-induced fibrosis. Inflammation 2008;31:299-303
   PubMed Web of Science ®Google Scholar
• Vannella KM, McMillan TR, Charbeneau RP, Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function. J Immunol 2007;179:7883-90
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Burdick MD, Hong K, Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114:438-46
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Ahmad A, Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 2010;13:109-18
   PubMed Web of Science ®Google Scholar
• Nagai T, Arao T, Furuta K, Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 2011;10:169-77
   PubMed Web of Science ®Google Scholar
• Farkas L, Farkas D, Gauldie J, Transient overexpression of gremlin results in epithelial activation and reversible fibrosis in rat lungs. Am J Respir Cell Mol Biol 2010
   Google Scholar
• Becerril C, Pardo A, Montano M, Acidic fibroblast growth factor induces an antifibrogenic phenotype in human lung fibroblasts. Am J Respir Cell Mol Biol 1999;20:1020-7
   PubMed Web of Science ®Google Scholar
• Ramos C, Montano M, Becerril C, Acidic fibroblast growth factor decreases alpha-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2006;291:L871-9
   PubMed Web of Science ®Google Scholar
• Ramos C, Becerril C, Montano M, FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol 2010;299:L222-31
   PubMed Web of Science ®Google Scholar
• Watanabe M, Ebina M, Orson FM, Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther 2005;12:58-67
   PubMed Web of Science ®Google Scholar
• Guo J, Yi ES, Havill AM, Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am J Physiol 1998;275:L800-5
   PubMed Web of Science ®Google Scholar
• Aguilar S, Scotton CJ, McNulty K, Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009;4:e8013
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Yazawa T, Baba Y, Keratinocyte growth factor gene transduction ameliorates pulmonary fibrosis induced by bleomycin in mice. Am J Respir Cell Mol Biol 2010
   Google Scholar
• Spielberger R, Stiff P, Bensinger W, Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8
   PubMed Web of Science ®Google Scholar
• Rubenstein EB, Peterson DE, Schubert M, Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100:2026-46
   PubMed Web of Science ®Google Scholar
• Kobbe G, Bruns I, Schroeder T, A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010;21:1898-904
   PubMed Web of Science ®Google Scholar
• Henderson WR Jr, Chi EY, Ye X, Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 2010;107:14309-14
   PubMed Web of Science ®Google Scholar
• Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 2010;298:L715-31
   PubMed Web of Science ®Google Scholar
• Weiss DJ, Kolls JK, Ortiz LA, Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008;5:637-67
   PubMedGoogle Scholar
• De Miguel MP, Fuentes-Julian S, Alcaina Y. Pluripotent stem cells: origin, maintenance and induction. Stem Cell Rev 2010;6:633-49
   PubMed Web of Science ®Google Scholar
• Wang D, Haviland DL, Burns AR, A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2007;104:4449-54
   PubMed Web of Science ®Google Scholar
• Wang D, Morales JE, Calame DG, Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. Mol Ther 2010;18:625-34
   PubMed Web of Science ®Google Scholar
• Wernig M, Meissner A, Foreman R, In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448:318-24
   PubMed Web of Science ®Google Scholar
• Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-17
   PubMed Web of Science ®Google Scholar
• Pfannkuche K, Hannes T, Khalil M, Induced pluripotent stem cells: a new approach for physiological research. Cell Physiol Biochem 2010;26:105-24
   PubMed Web of Science ®Google Scholar
• Somers A, Jean JC, Sommer CA, Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28:1728-40
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Gambelli F, McBride C, Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407-11
   PubMed Web of Science ®Google Scholar
• Rojas M, Xu J, Woods CR, Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005;33:145-52
   PubMed Web of Science ®Google Scholar
• Moodley Y, Atienza D, Manuelpillai U, Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 2009;175:303-13
   PubMed Web of Science ®Google Scholar
• Lee SH, Jang AS, Kim YE, Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respir Res 2010;11:16
   PubMed Web of Science ®Google Scholar
• Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol 2005;33:328-34
   PubMed Web of Science ®Google Scholar
• Chang JC, Summer R, Sun X, Evidence that bone marrow cells do not contribute to the alveolar epithelium. Am J Respir Cell Mol Biol 2005;33:335-42
   PubMed Web of Science ®Google Scholar
• Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 2010;21:1045-56
   PubMed Web of Science ®Google Scholar
• Riggi N, Suva ML, De Vito C, EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010;24:916-32
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Kota DJ, Bazhanov N, Reger RL. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med. 2010;14:2190-9
   PubMed Web of Science ®Google Scholar
• Price AP, England KA, Matson AM, Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A 2010;16:2581-91
   PubMed Web of Science ®Google Scholar
• Petersen TH, Calle EA, Zhao L, Tissue-engineered lungs for in vivo implantation. Science 2010;329:538-41
   PubMed Web of Science ®Google Scholar
• Pandit KV, Corcoran D, Yousef H, Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010;182:220-9
   PubMed Web of Science ®Google Scholar
• Liu G, Friggeri A, Yang Y, miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589-97
   PubMed Web of Science ®Google Scholar
• Cushing L, Kuang PP, Qian J, MIR-29 is a Major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2010
   Google Scholar
• Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010;70:7027-30
   PubMed Web of Science ®Google Scholar
• Kumar MS, Erkeland SJ, Pester RE, Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008;105:3903-8
   PubMed Web of Science ®Google Scholar
• Wiggins JF, Ruffino L, Kelnar K, Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923-30
   PubMed Web of Science ®Google Scholar